{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:11:25Z","timestamp":1777900285909,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["9039-00015B"],"award-info":[{"award-number":["9039-00015B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.autrev.2021.102829","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T03:39:29Z","timestamp":1618803569000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Vasculitis therapy refines vasculitis mechanistic classification"],"prefix":"10.1016","volume":"20","author":[{"given":"Christopher Kirkegaard","family":"Torp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Br\u00fcner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kresten Krarup","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen-Margrethe","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0005","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semarthrit.2013.07.010","article-title":"Biological therapy for systemic vasculitis: A systematic review","volume":"43","author":"Silva-Fernandez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102829_bb0010","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. 2012 [cited 2020 30 Jan]; Available from: https:\/\/www.vasculitisfoundation.org\/mcm_article\/update-the-new-2012-revised-international-chapel-hill-consensus-conference-nomenclature-of-vasculitides\/.","DOI":"10.1002\/art.37715"},{"key":"10.1016\/j.autrev.2021.102829_bb0015","author":"University of Oxford"},{"key":"10.1016\/j.autrev.2021.102829_bb0020","doi-asserted-by":"crossref","first-page":"102759","DOI":"10.1016\/j.autrev.2021.102759","article-title":"The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies","author":"Ramponi","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0025","doi-asserted-by":"crossref","first-page":"102708","DOI":"10.1016\/j.autrev.2020.102708","article-title":"Comorbidities and health-related quality of life in patients with Antineutrophil cytoplasmic antibody (ANCA) - associated vasculitis","volume":"20","author":"Mercuzot","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.berh.2018.07.006","article-title":"Conventional and biological immunosuppressants in vasculitis","volume":"32","author":"Guillevin","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102829_bb0035","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102829_bb0040","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102829_bb0045","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells","year":"2009"},{"issue":"3","key":"10.1016\/j.autrev.2021.102829_bb0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2021.102829_bb0055","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/03009742.2015.1060521","article-title":"Ustekinumab as a therapeutic option for Takayasu arteritis: From genetic findings to clinical application","volume":"45","author":"Terao","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102829_bb0065","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2021.102829_bb0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/rheumatology\/kex249","article-title":"Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature","volume":"57","author":"Pazzola","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0075","first-page":"171","article-title":"The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis","volume":"35 Suppl 103","author":"Zhou","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102829_bb0080","article-title":"Ustekinumab for the treatment of Giant cell arteritis","author":"Matza","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.autrev.2021.102829_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102829_bb0090","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102829_bb0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102829_bb0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0105","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.autrev.2021.102829_bb0110","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2021.102829_bb0115","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"issue":"1 Suppl 64","key":"10.1016\/j.autrev.2021.102829_bb0125","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: Long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102829_bb0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102829_bb0145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2021.102829_bb0150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2021.102829_bb0155","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in Giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10031","key":"10.1016\/j.autrev.2021.102829_bb0165","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.autrev.2021.102829_bb0170","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2021.102829_bb0175","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102829_bb0180","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102829_bb0185","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2021.102829_bb0190","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener\u2019s granulomatosis: A six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2021.102829_bb0195","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener\u2019s granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2021.102829_bb0200","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","article-title":"Rituximab for the treatment of Churg-Strauss syndrome with renal involvement","volume":"26","author":"Cartin-Ceba","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.autrev.2021.102829_bb0205","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/14397595.2016.1160968","article-title":"Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: A single-arm, single-center, clinical trial","volume":"26","author":"Sakai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102829_bb0210","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2021.102829_bb0215","doi-asserted-by":"crossref","first-page":"c89","DOI":"10.1159\/000319655","article-title":"Addition of infliximab to standard therapy for ANCA-associated vasculitis","volume":"117","author":"Morgan","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"10.1016\/j.autrev.2021.102829_bb0220","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102829_bb0225","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/ndt\/gfq187","article-title":"Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement","volume":"25","author":"Laurino","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2021.102829_bb0230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijcard.2017.12.066","article-title":"Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide","volume":"266","author":"Kong","year":"2018","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102829_bb0235","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00296-018-4159-1","article-title":"Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: A prospective single-arm study","volume":"38","author":"Park","year":"2018","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0240","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","article-title":"Interleukin-1 blockade in refractory giant cell arteritis","volume":"81","author":"Ly","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.autrev.2021.102829_bb0245","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1078\/0171-2985-00197","article-title":"Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade","volume":"206","author":"Arbach","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2021.102829_bb0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"5","key":"10.1016\/j.autrev.2021.102829_bb0255","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","article-title":"Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis","volume":"45","author":"Park","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2021.102829_bb0260","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","article-title":"Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis","volume":"36","author":"Roche","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"3 Suppl 97","key":"10.1016\/j.autrev.2021.102829_bb0265","first-page":"S21","article-title":"The critical role of IL-6 in the pathogenesis of Takayasu arteritis","volume":"34","author":"Kong","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/jhg.2015.87","article-title":"Revisited HLA and non-HLA genetics of Takayasu arteritis--where are we?","volume":"61","author":"Terao","year":"2016","journal-title":"J Hum Genet"},{"key":"10.1016\/j.autrev.2021.102829_bb0275","doi-asserted-by":"crossref","first-page":"43953","DOI":"10.1038\/srep43953","article-title":"Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy","volume":"7","author":"Carmona","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.autrev.2021.102829_bb0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajhg.2013.05.024","article-title":"Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population","volume":"93","author":"Terao","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.autrev.2021.102829_bb0285","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"\u2018MHC-I-opathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102829_bb0290","doi-asserted-by":"crossref","first-page":"102634","DOI":"10.1016\/j.autrev.2020.102634","article-title":"Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study","volume":"19","author":"Mertz","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2021.102829_bb0295","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14397595.2018.1546358","article-title":"Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy","volume":"29","author":"Yoshifuji","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0300","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/PAP.0000000000000154","article-title":"Pathophysiology of ANCA-associated Vasculitis","volume":"24","author":"Al-Hussain","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102829_bb0305","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2021.102829_bb0310","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: Characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"1 Suppl 64","key":"10.1016\/j.autrev.2021.102829_bb0315","first-page":"S23","article-title":"Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome","volume":"29","author":"Jakiela","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102829_bb0325","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1681\/ASN.2012020119","article-title":"Endothelium-neutrophil interactions in ANCA-associated diseases","volume":"23","author":"Halbwachs","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102829_bb0330","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102829_bb0335","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.autrev.2021.102829_bb0340","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2019.01.049","article-title":"CD28 signaling controls metabolic fitness of pathogenic T cells in medium and large vessel vasculitis","volume":"73","author":"Zhang","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102829_bb0345","doi-asserted-by":"crossref","first-page":"E970","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.autrev.2021.102829_bb0350","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF03401699","article-title":"Giant cell vasculitis is a T cell-dependent disease","volume":"3","author":"Brack","year":"1997","journal-title":"Mol Med"},{"issue":"7","key":"10.1016\/j.autrev.2021.102829_bb0355","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.39130","article-title":"14-3-3 in thoracic aortic aneurysms: Identification of a novel autoantigen in large vessel vasculitis","volume":"67","author":"Chakravarti","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102829_bb0360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2019.02.007","article-title":"Cytokines, growth factors and proteases in medium and large vessel vasculitis","volume":"206","author":"Weyand","year":"2019","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102829_bb0365","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.39157","article-title":"Takayasu arteritis and ulcerative colitis: High rate of co-occurrence and genetic overlap","volume":"67","author":"Terao","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102829_bb0370","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.autrev.2021.102829_bb0375","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-017-1408-8","article-title":"A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production","volume":"19","author":"Nakajima","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1 Suppl 57","key":"10.1016\/j.autrev.2021.102829_bb0380","first-page":"62","article-title":"Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)","volume":"28","author":"Schneeweis","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102829_bb0385","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/37.7.797","article-title":"Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis","volume":"37","author":"Pountain","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102829_bb0390","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: A comprehensive review on the role of IL-1\u03b1 in the pathogenesis and targeted treatment of autoimmune and inflammatory diseases","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102829_bb0395","series-title":"Clinical Commisioning Policy: Anakinra to treat periodic fevers and autoinflammatory disorders (all ages)","author":"NHS England Specialised Services Clinical Reference Group for Immunology and Allergy CRG","year":"2018"},{"key":"10.1016\/j.autrev.2021.102829_bb0400","series-title":"Clinical Comissioning Policy: Anakinra\/tocilizumab for the treatment of Adult-Onset Still's Disease refractory to second-line therapy (adults)","author":"NHS England Specialised Services Clinical Reference Group for Specialised Immunology and Allergy Services","year":"2018"},{"key":"10.1016\/j.autrev.2021.102829_bb0405","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2014.01.017","article-title":"The diagnosis and classification of giant cell arteritis","volume":"48-49","author":"Nesher","year":"2014","journal-title":"J Autoimmun"},{"issue":"8","key":"10.1016\/j.autrev.2021.102829_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:41Z","timestamp":1761600161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1568997221001014"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102829","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasculitis therapy refines vasculitis mechanistic classification","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}